Ee Siang Choong1, Serigne Lo2, Martin Drummond2, Gerald B Fogarty3, Alexander M Menzies4, Alexander Guminski4, Brindha Shivalingam5, Kathryn Clarke6, Georgina V Long4, Angela M Hong7. 1. Chris O Brien Lifehouse, Camperdown, NSW, Australia. 2. Melanoma Institute Australia, The University of Sydney, NSW, Australia. 3. Melanoma Institute Australia, The University of Sydney, NSW, Australia; Genesis Cancer Care, Mater Radiation Oncology, North Sydney, Australia; Mater Hospital, North Sydney NSW, Australia. 4. Melanoma Institute Australia, The University of Sydney, NSW, Australia; Mater Hospital, North Sydney NSW, Australia; Royal North Shore Hospital, St Leonards, NSW, Australia. 5. Melanoma Institute Australia, The University of Sydney, NSW, Australia; Royal Prince Alfred Hospital, Camperdown, NSW Australia; Mater Hospital, North Sydney NSW, Australia. 6. Genesis Cancer Care, Mater Radiation Oncology, North Sydney, Australia. 7. Melanoma Institute Australia, The University of Sydney, NSW, Australia; Genesis Cancer Care, Mater Radiation Oncology, North Sydney, Australia; Mater Hospital, North Sydney NSW, Australia. Electronic address: angela.hong@sydney.edu.au.
Abstract
INTRODUCTION: With new systemic therapies demonstrating activity in melanoma brain metastasis, most of the previously reported stereotactic radiosurgery (SRS) data are superseded. In this study, we report the outcomes (overall survival [OS] and brain control [BC]) and identify factors that associate with such outcomes in the era of modern systemic therapy. METHOD: A total of 108 patients treated with SRS from 2010 to 2015 were included. Systemic treatment use within 6 weeks of SRS was noted. OS was defined as time from SRS to death or last follow-up, and BC was defined as absence of any active intracranial disease during follow-up. Univariate and multivariate Cox proportional hazard analyses were performed on clinico-pathological prognostic features associated with OS and BC. RESULTS: The median age was 64.3 years, and the median follow-up was 8.6 months. Seventy-nine (73.1%) patients received systemic treatment. The median OS were as follows: anti-CTLA4 - 7.5 months (95% CI: 4.4-15.6), anti-PD1 - 20.4 months (95% CI: 8.8 - N/A) and BRAF inhibitor (BRAFi) ± MEK inhibitor (MEKi) - 17.8 months (95% CI: 11.8 - N/A). Median BC was as follows: anti-CTLA4 - 7.5 months (95% CI: 4.0-15.6), anti-PD1 - 12.7 months (95% CI: 5.5 - N/A) and BRAFi ± MEKi - 12.7 months (95% CI: 8.3-18.5). In multivariate analysis, age and type of systemic therapy were strongly associated with OS. Age, Eastern Cooperative Oncology Group performance status, Graded Prognostic Assessment (GPA) score, and presence of symptoms were associated with BC. CONCLUSIONS: Favourable outcomes are seen in patients treated with SRS and with the best survival seen in patients treated with anti-PD1. Known independent prognostic factors for survival such as age and performance status and GPA score remain relevant in this setting.
INTRODUCTION: With new systemic therapies demonstrating activity in melanoma brain metastasis, most of the previously reported stereotactic radiosurgery (SRS) data are superseded. In this study, we report the outcomes (overall survival [OS] and brain control [BC]) and identify factors that associate with such outcomes in the era of modern systemic therapy. METHOD: A total of 108 patients treated with SRS from 2010 to 2015 were included. Systemic treatment use within 6 weeks of SRS was noted. OS was defined as time from SRS to death or last follow-up, and BC was defined as absence of any active intracranial disease during follow-up. Univariate and multivariate Cox proportional hazard analyses were performed on clinico-pathological prognostic features associated with OS and BC. RESULTS: The median age was 64.3 years, and the median follow-up was 8.6 months. Seventy-nine (73.1%) patients received systemic treatment. The median OS were as follows: anti-CTLA4 - 7.5 months (95% CI: 4.4-15.6), anti-PD1 - 20.4 months (95% CI: 8.8 - N/A) and BRAF inhibitor (BRAFi) ± MEK inhibitor (MEKi) - 17.8 months (95% CI: 11.8 - N/A). Median BC was as follows: anti-CTLA4 - 7.5 months (95% CI: 4.0-15.6), anti-PD1 - 12.7 months (95% CI: 5.5 - N/A) and BRAFi ± MEKi - 12.7 months (95% CI: 8.3-18.5). In multivariate analysis, age and type of systemic therapy were strongly associated with OS. Age, Eastern Cooperative Oncology Group performance status, Graded Prognostic Assessment (GPA) score, and presence of symptoms were associated with BC. CONCLUSIONS: Favourable outcomes are seen in patients treated with SRS and with the best survival seen in patients treated with anti-PD1. Known independent prognostic factors for survival such as age and performance status and GPA score remain relevant in this setting.
Authors: Ines Pires da Silva; Isabella C Glitza; Lauren E Haydu; Romany Johnpulle; Patricia D Banks; George D Grass; Simone M A Goldinger; Jessica L Smith; Ashlyn S Everett; Peter Koelblinger; Rachel Roberts-Thomson; Michael Millward; Victoria G Atkinson; Alexander Guminski; Rony Kapoor; Robert M Conry; Matteo S Carlino; Wei Wang; Mark J Shackleton; Zeynep Eroglu; Serigne Lo; Angela M Hong; Georgina V Long; Douglas B Johnson; Alexander M Menzies Journal: Pigment Cell Melanoma Res Date: 2019-03-03 Impact factor: 4.693
Authors: Lukas W Pfannenstiel; Corey McNeilly; Chaomei Xiang; Kai Kang; Claudia Marcella Diaz-Montero; Jennifer S Yu; Brian R Gastman Journal: Oncoimmunology Date: 2018-10-11 Impact factor: 8.110
Authors: Pierre-Yves Borius; Jean Régis; Alexandre Carpentier; Michel Kalamarides; Charles Ambroise Valery; Igor Latorzeff Journal: Cancer Metastasis Rev Date: 2021-01-04 Impact factor: 9.264
Authors: Tyler P Robin; Robert E Breeze; Derek E Smith; Chad G Rusthoven; Karl D Lewis; Rene Gonzalez; Amanda Brill; Robin Saiki; Kelly Stuhr; Laurie E Gaspar; Sana D Karam; David Raben; Brian D Kavanagh; Sameer K Nath; Arthur K Liu Journal: J Neurooncol Date: 2018-06-16 Impact factor: 4.130
Authors: Saksham Gupta; Hassan Dawood; Alexandra Giantini Larsen; Luis Fandino; Erik H Knelson; Timothy R Smith; Eudocia Q Lee; Ayal Aizer; Ian F Dunn; Wenya Linda Bi Journal: Front Oncol Date: 2021-05-05 Impact factor: 6.244
Authors: Stephanie Kim Cheok; Azeet Narayan; Anna Arnal-Estape; Scott Gettinger; Sarah B Goldberg; Harriet M Kluger; Don Nguyen; Abhijit Patel; Veronica Chiang Journal: JCO Precis Oncol Date: 2021-01-12